Short description
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
Description
NicOx is a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Valbonne, Provence-Alpes-Cote d'Azur, France, Europe
Founded on
January 1, 1996
Exited on
April 28, 2023
Went public on
April 28, 2023
Stock symbol
ALCOX
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccessforu
Sign in for full access
Founders
Elisabeth Robinson, John L. Wallace, Michele Garufi